D C Klonoff

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Inhaled insulin
    D C Klonoff
    University of California at San Francisco, Burlingame, California, USA
    Diabetes Technol Ther 1:307-13. 1999
  2. ncbi request reprint A flaw in the use of sulfonylurea screening to diagnose sulfonylurea overdosages
    David C Klonoff
    Dorothy L and James E Frank Diabetes Research Institute, Mills Peninsula Health Services, San Mateo, California 94401, USA
    Diabetes Technol Ther 5:453-4. 2003
  3. ncbi request reprint An economic analysis of interventions for diabetes
    D C Klonoff
    Department of Medicine, University of California at San Francisco, USA
    Diabetes Care 23:390-404. 2000
  4. ncbi request reprint A review of continuous glucose monitoring technology
    David C Klonoff
    University of California San Francisco, San Francisco, California, USA
    Diabetes Technol Ther 7:770-5. 2005
  5. ncbi request reprint Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery
    David C Klonoff
    Mills Peninsula Diabetes Research Institute, San Mateo, California 94401, USA
    Pediatr Endocrinol Rev 1:94-100. 2003
  6. ncbi request reprint Continuous glucose monitoring: roadmap for 21st century diabetes therapy
    David C Klonoff
    Mills Peninsula Health Services Diabetes Research Institute, 100 S San Mateo Dr, Rm 3124, San Mateo, CA 94401, USA
    Diabetes Care 28:1231-9. 2005
  7. ncbi request reprint Current, emerging, and future trends in metabolic monitoring
    David C Klonoff
    Diabetes Technol Ther 4:583-8. 2002
  8. ncbi request reprint The First Annual Diabetes Technology Meeting--a new forum for accelerating the development of technology to fight diabetes
    David C Klonoff
    Diabetes Technol Ther 4:201-2. 2002
  9. ncbi request reprint Subcutaneous continuous glucose monitoring in severe burn patients
    David C Klonoff
    Crit Care Med 35:1445; author reply 1445-6. 2007
  10. ncbi request reprint Time synching or time sinking?
    Daniel J Crowe
    Diabetes Technol Ther 7:663-4. 2005

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Inhaled insulin
    D C Klonoff
    University of California at San Francisco, Burlingame, California, USA
    Diabetes Technol Ther 1:307-13. 1999
    ..Inhaled insulin will become established if ongoing studies continue to demonstrate this technology to be safe and effective...
  2. ncbi request reprint A flaw in the use of sulfonylurea screening to diagnose sulfonylurea overdosages
    David C Klonoff
    Dorothy L and James E Frank Diabetes Research Institute, Mills Peninsula Health Services, San Mateo, California 94401, USA
    Diabetes Technol Ther 5:453-4. 2003
  3. ncbi request reprint An economic analysis of interventions for diabetes
    D C Klonoff
    Department of Medicine, University of California at San Francisco, USA
    Diabetes Care 23:390-404. 2000
    ..Widely practiced interventions for patients with diabetes can be clearly cost-saving and clearly cost-effective. These practices are attractive from both a medical and an economic perspective...
  4. ncbi request reprint A review of continuous glucose monitoring technology
    David C Klonoff
    University of California San Francisco, San Francisco, California, USA
    Diabetes Technol Ther 7:770-5. 2005
  5. ncbi request reprint Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery
    David C Klonoff
    Mills Peninsula Diabetes Research Institute, San Mateo, California 94401, USA
    Pediatr Endocrinol Rev 1:94-100. 2003
    ..new routes of insulin administration, including inhaled, oral, buccal, nasal, and transdermal drug delivery systems. These new technologies will facilitate proper treatment of type 1 diabetes and improve the lives of affected patients...
  6. ncbi request reprint Continuous glucose monitoring: roadmap for 21st century diabetes therapy
    David C Klonoff
    Mills Peninsula Health Services Diabetes Research Institute, 100 S San Mateo Dr, Rm 3124, San Mateo, CA 94401, USA
    Diabetes Care 28:1231-9. 2005
  7. ncbi request reprint Current, emerging, and future trends in metabolic monitoring
    David C Klonoff
    Diabetes Technol Ther 4:583-8. 2002
  8. ncbi request reprint The First Annual Diabetes Technology Meeting--a new forum for accelerating the development of technology to fight diabetes
    David C Klonoff
    Diabetes Technol Ther 4:201-2. 2002
  9. ncbi request reprint Subcutaneous continuous glucose monitoring in severe burn patients
    David C Klonoff
    Crit Care Med 35:1445; author reply 1445-6. 2007
  10. ncbi request reprint Time synching or time sinking?
    Daniel J Crowe
    Diabetes Technol Ther 7:663-4. 2005
  11. ncbi request reprint Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    John B Buse
    Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Clin Ther 29:139-53. 2007
    ..Some patients were followed up in open-label extensions to provide 'real-world' exenatide clinical experience...
  12. ncbi request reprint An adaptive drug infusion system
    Meghan Simmons
    TheraFuse, Inc, Carlsbad, California 92008, USA
    Diabetes Technol Ther 6:607-20. 2004
    ....
  13. ncbi request reprint The need for separate performance goals for glucose sensors in the hypoglycemic, normoglycemic, and hyperglycemic ranges
    David C Klonoff
    Diabetes Care 27:834-6. 2004
  14. ncbi request reprint Microdialysis of interstitial fluid for continuous glucose measurement
    David C Klonoff
    Diabetes Technol Ther 5:539-43. 2003
  15. ncbi request reprint The link between diabetes, military metabolic monitoring, and NASA
    David C Klonoff
    Diabetes Technol Ther 5:351-3. 2003
  16. ncbi request reprint Diabetes and telemedicine: is the technology sound, effective, cost-effective, and practical?
    David C Klonoff
    Diabetes Care 26:1626-8. 2003
  17. ncbi request reprint European trends in diabetes technology--continuous glucose measurements and computerized information-processing tools
    David C Klonoff
    Diabetes Technol Ther 4:763-4. 2002
  18. ncbi request reprint Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    David C Klonoff
    Diabetes Research Institute, Mills Peninsula Health Services, San Mateo, CA, USA
    Curr Med Res Opin 24:275-86. 2008
    ..The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic markers, and safety...